From treatment adherence to advanced shared decision making: New professional strategies and attitudes in mental health care

Current Clinical Pharmacology

Volumn 6, Issue 2, 2011, Pages 91-99

  Tibaldi, Giuseppe ^a   Salvador Carulla, Luis ^b   García Gutierrez, Juan Carlos ^c  

^a Centro Studi e Ricerche in Psichiatria   (Italy)

^b PSICOST Research Association   (Spain)

^c HOSPITAL UNIVERSITARIO DE PUERTO REAL   (Spain)

Author keywords

Mental health; Person centred medicine; Shared decision making; Treatment adherence

Indexed keywords

ANTIDEPRESSANT AGENT; NEUROLEPTIC AGENT; PSYCHOTROPIC AGENT;

ARTICLE; ATTITUDE; BIOTECHNOLOGY; CLINICAL DECISION MAKING; CLINICAL EFFECTIVENESS; CLINICAL TRIAL (TOPIC); COMMUNITY CARE; CONCEPTUAL FRAMEWORK; CONVALESCENCE; DEPRESSION; DISTRESS SYNDROME; DOCTOR PATIENT RELATION; DRUG DEPENDENCE; DRUG EFFICACY; DRUG INDUSTRY; DRUG SAFETY; EMPOWERMENT; FAMILY RELATION; HEALTH BELIEF; HOLISTIC CARE; HUMAN; INTERPERSONAL COMMUNICATION; MENTAL HEALTH CARE; MENTAL HEALTH CARE PERSONNEL; META ANALYSIS; MOTIVATION; PATIENT CARE; PATIENT COMPLIANCE; PATIENT COUNSELING; PATIENT PREFERENCE; PRACTICE GUIDELINE; PRESCRIPTION; PRIORITY JOURNAL; PROFESSIONAL KNOWLEDGE; PSYCHOSIS; PSYCHOTHERAPY; RISK FACTOR; SCHIZOPHRENIA; SEDATION; SHARED DECISION MAKING; SIDE EFFECT; STRATEGIC PLANNING; SYSTEMATIC REVIEW; TREATMENT OUTCOME;

ATTITUDE OF HEALTH PERSONNEL; COUNSELING; CULTURE; DECISION MAKING; FAMILY; HUMANS; MEDICATION ADHERENCE; MENTAL DISORDERS; PATIENT PARTICIPATION; PHYSICIAN-PATIENT RELATIONS;

EID: 79959327652     PISSN: 15748847     EISSN: 15748847     Source Type: Journal    
DOI: 10.2174/157488411796151101     Document Type: Article

References (111)

1. Gilmer TP, Dolder CR, Lacro JP, et al. Adherence to treatment with antipsychotic medication and health care costs among medicaid beneficiaries with schizophrenia. Am J Psychiatr 2004; 161: 692-9.
2. Wade AG, Häring J. A review of the costs associated with depression and treatment noncompliance: The potential benefits of online support. Int Clin Psychopharmacol 2010; 25: 288-96.
3. Julius RJ, Novitsky MA Jr, Dubin WR. Medication adherence: a review of the literature and implications for clinical practice. J Psychiatr Pract 2009; 15: 34-44.
4. Roca M, Armengol S, Salvador-Carulla L, Monzón S, Salvà J, Gili M. Adherence to medication in depressive patients. J Clin Psychopharmacol 2011; 31(4): (in press).
5. Velligan DI, Weiden PJ, Sajatovic M, et al. expert consensus panel on adherence problems in serious and persistent mental illness. The expert consensus guideline series: adherence problems in patients with serious and persistent mental illness. J Clin Psychiatr 2009; 70 (Suppl 4): 1-46.
6. Weiden PJ, Kozma C, Grogg A, Locklear J. Partial compliance and risk of rehospitalizaiton among California Medicaid patients with schizophrenia. Psychiatr Serv 2004; 55: 886-91.
7. Puschner B, Angermeyer MC, Leese M, et al. Course of adherence to medication and quality of life in people with schizophrenia. Psychiatr Res 2009; 165: 224-33.
8. Meier J, Becker T, Patel A, et al. Effect of medication-related factors on adherence in people with schizophrenia: a European multi-centre study. Epidemiol Psichiatr Soc 2010; 19: 251-9.
9. McCartney G, Hanlon P. What can health professionals contribute to the challenge of sustainability? Public Health 2009; 123: 761-4.
10. Grandes G, Sanchez A, Sanchez-Pinilla RO, et al. Effectiveness of physical activity advice and prescription by physicians in routine primary care: A cluster randomized trial. Arch Intern Med 2009; 169: 694-701.
11. Jansink R, Braspenning J, van der Weijden T, Niessen L, Elwyn G, Grol R. Nurse-led motivational interviewing to change the lifestyle of patients with type 2 diabetes (mild-project): Protocol for a cluster, randomized, controlled trial on implementing lifestyle recommendations. BMC Health Serv Res 2009; 9: 19.
12. Grandes G, Sanchez A, Cortada JM, et al. Is integration of healthy lifestyle promotion into primary care feasible? Discussion and consensus sessions between clinicians and researchers. BMC Health Serv Res 2008; 8: 213.
13. Sanchez A, Grandes G, Cortada JM, Pombo H, Balague L, Calderon C. Modelling innovative interventions for optimising healthy lifestyle promotion in primary health care: Prescribe vida saludable Phase I research protocol. BMC Health Serv Res 2009; 9: 103.
14. Korhonen I, Mattila E, Ahtinen A, et al. Personal health promotion through personalized health technologies - Nuadu experience. Conf Proc IEEE Eng Med Biol Soc 2009; 1: 316-9.
15. Horne R. Beliefs and adherence to treatment: the challenge for research and clinical practice. In: Halligan PW, Aylward M. Eds. The Power of Belief: Psychosocial Influence on Illness, Disability and Medicine. Oxford, Oxford University Press. 2006; p. 115-36.
16. Tibaldi G, Clatworthy J, Torchio E, Argentero P, Munizza C, Horne R. The utility of the necessity-concerns framework in explaining treatment non-adherence in four chronic Illness groups in Italy. Chronic Illn 2009; 5: 129-33.
17. Horne R, Weinman J. Patients' beliefs about prescribed medicines and their role in adherence to treatment in chronic physical illness. J. Psychosom Res 1999; 47: 555-67.
18. Pound P, Britten N, Morgan M, et al. Resisting medicines: a synthesis of qualitative studies of medicine taking. Soc Sci Med 2005; 61: 133-55.
19. Townsend A, Hunt K, Wyke S. Managing multiple morbidity in mid-life: A qualitative study of attitudes to drug use. Br Med J 2003; 327: 837-42.
20. Pampallona S, Bollini P, Tibaldi G, Kupelnick B, Munizza C. Patient adherence in the treatment of depression. Br J Psychiatr 2002; 180: 104-9.
21. Bollini P, Pampallona S, Kupelnick B, Tibaldi G, Munizza C. Improving compliance in depression: a summary of recommendations found in published reviews. J Clin Pharm Ther 2006; 31: 253-60.
22. Institute of Medicine, Committee on Quality of Health Care in America. Crossing the Quality Chasm: A New Health System for the 21st Century. National Academies Press: Washington 2001.
23. Angermeyer MC, Matschinger H. Public attitude towards psychiatric treatment. Acta Psychiatr Scand 1996; 94: 326-36.
24. Barney LJ, Griffiths KM, Jorm AF, Christensen H. Stigma about depression and its impact on help-seeking intentions. Aust N Z J Psychiatr 2006; 40: 51-4.
25. Binkin N, Gigantesco A, Ferrante G, Baldissera S. Depressive symptoms among adults 18-69 years in Italy: results from the Italian behavioural risk factor surveillance system, 2007. Int J Public Health 2010; 55: 449-88.
26. Barbui C, Tansella M. Identification and management of depression in primary care settings. A meta-review of evidence. Epidemiol Psichiatr Soc 2006; 15: 287-3
27. Fischer W, Goerg D, Zbinden E, Guimon J. Determining factors and the effects of attitudes towards psychotropic medication. In: Guimon J, Fischer W, Sartorius N. Eds. The image of madness: the public facing mental illness and psychiatric treatment. Basel, Karger 1999; 162-86.
28. Kohn R, Saxena S, Levav I, Saraceno B. The treatment gap in mental health care. Bull World Health Organ 2004; 82: 858-66.
29. Jorm AF, Korten AE, Jacomb PA, Christensen H, Rodgers B, Pollitt P. Mental health literacy: A survey of the public's ability to recognise mental disorders and their beliefs about the effectiveness of treatment. Med J Aust 1997; 166: 182-6.
30. Priest RG, Vize C, Roberts A, Roberts M, Tylee A. Lay people's attitudes to treatment of depression: results of opinion poll for Defeat Depression Campaign just before its launch. Br Med J 1996; 313: 858-9.
31. Jorm AF, Korten AE, Rodgers B, et al. Belief systems of the general public concerning the appropriate treatments for mental disorders. Soc Psychiatr Psychiatr Epidemiol 1997; 32: 468-43.
32. Jorm AF. Mental health literacy-public knowledge and beliefs about mental disorders. Bri J Psychiatr 2000; 177: 396-401.
33. Comas A, Alvarez E. Knowledge and perception about depression in the spanish population. Actas Esp Psiquiatr 2004; 32: 371-6.
34. Wang J, Lai D. The relationship between mental health literacy, personal contacts and personal stigma against depression. J Aff ect Disord 2008; 110: 191-6.
35. Lauber C, Nordt C, Falcato L, Rössler W. Do people recognise mental illness? Factors influencing mental health literacy. Eur Arch Psychiatry Clin Neurosci 2003; 253: 248-51.
36. Link BG, Phelan JC, Bresnahan M, Stueve A, Pescosolido BA. Public conceptions of mental illness: labels, causes, dangerousness, and social distance. Am J Public Health 1999; 89: 1328-33.
37. Magliano L, Fiorillo A, De Rosa C, Malangone C, Maj M. Beliefs About Schizophrenia in Italy: A Comparative Nationwide Survey of the General Public, Mental Health Professionals, and Patients' Relatives. Can J Psychiatr 2004; 49: 171-9.
38. Petrie KJ, Weinman JA. Perceptions of health and illness: Current research and applications. Harwood Academic Publishers: Amsterdam 1997.
39. Kadam UT, Croft P, McLeod J, Hutchinson M. A qualitative study of patients' views on anxiety and depression. Br J Gen Pract 2001; 51: 375-80.
40. Prins MA, Verhaak PFM, van der Meer K, Penninx BWJH, Bensing JM. Primary care patients with anxiety and depression: Need for care from the patient's perspective. J Affect Disord 2009; 119: 163-71.
41. Bushnell J, McLeod D, Dowell A, et al. Do patients want to disclose psychological problems to GPs? Fam Pract 2005; 22: 631-37.
42. van Schaik DJF, Klijn AF, van Hout HPJ, et al. Patients' preferences in the treatment of depressive disorder in primary care. Gen Hosp Psychiatr 2004; 26: 184-9.
43. Brown C, Battista DR, Bruehlman R, Sereika SS, Thase ME, Dunbar-Jacob J. Beliefs about antidepressant medications in primary care patients: Relationship to self-reported adherence. Med Care 2005; 43: 1203-7.
44. Rethink Self Management Project. The experiences and views of self-management of people with a schizophrenia diagnosis (Initial Report) 2006; http://www.rethink.org/living-with-mental-illness/everyday-living/selfmanagement/index.html (accessed February 22nd, 2011).
45. Hopper K. Rethinking social recovery in schizophrenia: what a capabilities approach might offer. Soc Sci Med 2007; 65: 868-79.
46. Ciompi L, Harding CM, Lehtinen K. Deep concern. Schizophr Bull 2010; 36: 437-9.
47. Cooper LA, Gonzales JJ, Gallo JJ, et al. The acceptability of treatment for depression among African-American, Hispanic and White primary care patients. Med Care 2003; 41: 479-89.
48. Givens JL, Datto CJ, Ruckdeschel K, et al. Older patients' aversion to antidepressants: A qualitative study. J Gen Intern Med 2006; 21: 146-51.
49. van Voorhees BW, Fogel J, Houston TK, Cooper LA, Wang NY, Ford DE. Beliefs and attitudes associated with the intention to not accept the diagnosis of depression among young adults. Ann Fam Med 2005; 3: 38-46.
50. Nolan P, Badger F. Aspects of the relationship between doctors and depressed patients that enhance satisfaction with primary care. J Psychiatr Ment Health Nurs 2005; 12: 146-53.
51. Aikens JE, Nease DEJ, Nau DP, Klinkman MS, Schwenk TL. Adherence to maintenance-phase antidepressant medication as a function of patient beliefs about medication. Ann Fam Med 2005; 3: 23-30.
52. Moynihan R, Heath I, Henry D. Selling sickness: the pharmaceutical industry and disease mongering. Br Med J 2002; 324: 886-91.
53. Safer DJ. Design and reporting modifications in industry sponsored comparative psychopharmacology trials. J Nerv Ment Dis 2002; 190: 583-92.
54. Melander H, Ahlqvist-Rastad I, Meijer G, Beermann B. Evidence b(i)ased medicine-selective reporting from studies sponsored by the pharmaceutical industry: review of studies in new drug applications. Br Med J 2003; 326: 1171-3.
55. Moncrieff J, Crawford M. British psychiatry in the twentieth century - observations from a psychiatric journal. Soc Sci Med 2001; 53: 349-56.
56. Thomas P, Bracken P. Critical psychiatry in practice. Adv Psychiatr Treatment 2004; 10: 361-70.
57. Deegan PE, Drake RE. Shared decision making and medication management in the recovery process. Psychiatr Serv 2006; 57: 1636-9.
58. Hamann J, Cohen R, Leucht S, Busch R, Kissling W. Do patients with schizophrenia wish to be involved in decisions about their medical treatment? Am J Psychiatr 2005; 162: 2383-4.
59. Garfield S, Francis SA, Smith FJ. Building concordant relationships with patients starting antidepressant medication. Patient Educ Couns 2004; 55: 241-6.
60. Swartz MS, Stroup TS, McEvoy JP, Davis SM, Rosenheck RA, Keefe RS, Hsiao JK, Liberman JA. What CATIE Found: Results From the Schizophrenia Trial Psychiatr Serv 2008; 59: 500-506.
61. Lehman AF. Adopting Evidence-Based Practices-Our Hesitation Waltz. Schizophr Bull 2010; 36: 1-2.
62. Thornley B, Adams C. Content and quality of 2000 controlled trials in Schizophrenia over 50 years. Br Med J 1998; 317: 1181-4.
63. Pampallona S, Bollini P, Tibaldi G, Kupelnick B, Munizza C. Combined pharmacotherapy and psychological treatment for depression improves efficacy by enhancing adherence: systematic review. Arch Gen Psychiatr 2004; 61: 714-719.
64. Lenroot R, Bustillo JR, Lauriello J, Keith SJ. Integrated Treatment of Schizophrenia Psychiatr Serv 2003; 54: 1499-507.
65. Petersen L, Nordentoft M, Jeppesen P, et al. Improving 1-year outcome in first episode psychosis - OPUS trial. Br J Psychiatry 2005; 187 (Suppl. 48): 98-103.
66. Rosenheck RA. The Integration-Fragmentation Paradox. Psychiatr Serv 2007; 57: 909.
67. Kreyenbuhl J, Buchanan WR, Dickerson FB, Dixon LB. The Schizophrenia Patient Outcomes Research Team.: Updated Treatment Recommendations. Schizophr Bull 2010; 36: 94-103.
68. Davidson L. PORT through a recovery lens. Schizophr Bull 2010; 36: 107-8.
69. Davidson L, O'Connell M, Tondora J, Styron T, Kangas K. The Top Ten Concerns About Recovery Encountered in Mental Health System Transformation. Psychiatr Serv 2006; 57: 640-45.
70. Deegan PE. The importance of personal medicine: a qualitative study of resilience in people with psychiatric disabilities. Scand J Public Health Suppl 2005; 66: 29-35.
71. Bleuler M. Die schizophrenen Geistesstorungen im Lichte langjahriger Kranken-und Familiengeschichten. Georg Thieme: Stuttgart 1972.
72. Ciompi L, Muller C. Lebensweg und Alter der Schizophrenen: eine katamnestische Longzeitstudie bis ins Senium [Life Course and Old Age of Schizophrenics. A Catamnestic Long-Term Study until the Old Age]. Springer-Verlag: Berlin 1976.
73. DeSisto M, Harding CM, Ashikaga T, McCormick R, Brooks GW. The Maine and Vermont three-decade studies of serious mental illness: matched comparison of cross-sectional outcome. Br J Psychiatr 1985; 167: 338-342.
74. Harding CM, Brooks GW, Ashikaga T, Strauss JS, Breier A. The Vermont longitudinal study of persons with severe mental illness: I. Methodology, study, sample, and overall status 32 years later. Am J Psychiatry 1987; 144: 718-726.
75. Hinterhuber H. Zur katamnese der schizophrenien [On the catamnesis of schizophrenics]. Fortschr Neurol Psychiatr 1973; 41: 527-588.
76. Huber G, Gross G, Schuttler R. Schizophrenie: Verlaufs und sozialpsychiatrische Langzeituntersuchungen an den 1945 bis 1959 in Bonn hospitalisierten schizophrenen Kranken [Schizophrenia. Long-Term Investigations on the Course and Social Situation of Schizophrenics Recovered in Bonn 1945-1959]. Monographien aus dem Gesamtgebiete der Psychiatrie Bd. 21. Springer-Verlag: Berlin 1979.
77. Kreditor DKh. Late catamnesis of recurrent schizophrenia with prolonged remissions (according to an unselected study). Zh Nevrol Psikhiatr Im S S Korsakova 1977; 77: 110-113.
78. Marinow A. Klinisch-statische und katamnestische untersuchungen an chronisch Schizophrenen 1951-1960 und 1961-1970 [Clinicalstatistical and catamnestic investigations on chronic schizophrenics 1959-1960 and 1961-1970]. Archiv Psychiatr Nervenkrankheiten 1974; 218: 115-124.
79. Ogawa K, Miya M, Watarai A, Nakazawa M, Yuasa S, Utena H. A long-term follow-up study of schizophrenia in Japan-with special reference to the course of social adjustment. Br J Psychiatr 1987; 151: 758-765.
80. Tsuang MT, Woolson RF, Fleming JA. Long-term outcome of major psychoses. 1. Schizophrenia and affective disorders compared with psychiatrically symptom-free surgical conditions. Arch Gen Psychiatry 1979; 36: 1295-2131.
81. Harrow M, Jobe TH. How frequent is chronic multiyear delusional activity and recovery in schizophrenia: a 20-year multi-follow-up. Schizophr Bull. 2010; 36: 192-204.
82. Menezes NM, Arenovich T, Zipursky RB. A systematic review of longitudinal outcome studies of first-episode psychosis. Psychol Med. 2006; 36: 1349-1362.
83. Roberts GA Narrative and severe mental illness: what place do stories have in an evidence-based world? Adv Psych Treatment. 2000; 6: 432-441.
84. Drake RE, Deegan PE. Shared decision making is an ethical imperative Psychiatr Serv. 2009; 60: 1009.
85. Tibaldi G, Govers L. Evidence based hope for recovery from "schizophrenia". A common objective for all stakeholders in the mental health field. Psychosis 2011 (In press)
86. Baronet AM. Factors associated with caregiver burden in mental illness: a critical review of the research literature. Clin Psychol Rev. 1999; 19: 819-841.
87. Magliano L, Fiorillo A, De Rosa C, Malangone C, Maj M. for National Mental Health Project Working Group. Family burden in long-term diseases: a comparative study in schizophrenia vs physical disorders. Soc Sci Med 2005; 61: 313-322.
88. Barbato A, D'Avanzo B. Family interventions in schizophrenia and related disorders: a critical review of clinical trials. Acta Psychiatr Scand. 2000; 102: 81-97.
89. Dixon L, Adams C, Lucksted A. Update on family psychoeducation for schizophrenia. Schizophr Bull 2000; 26: 5-20.
90. Dixon L, McFarlane WR, Lefley H, Lucksted A, Cohen M, Falloon I, Mueser K, Miklowitz D, Solomon P, Sondheimer D. Evidencebased practices for services to families of people with psychiatric disabilities. Psychiatr Serv. 2001; 52: 903-910.
91. Magliano L, Marasco C, Fiorillo A, Malangone C, Guarneri M, Maj M. The impact of professional and social network support on the burden of families of patients with schizophrenia in Italy. Acta Psychiatr Scand. 2002; 106: 291-298.
92. Srebnik DS, Russo J, Sage J, Peto T, Zick E. Interest in psychiatric advance directives among high users of crisis services and hospitalization. Psychiatr Serv. 2003; 54: 981-986.
93. Buchanan A. Principal/agent theory and decision making in health care. Bioethics. 1988; 2(4):317-33.
94. Salvador-Carulla L, Melgarejo M. Treatment compliance: the medical challenge of the XXI century [Cumplimiento terapéutico: El reto de la medicina del siglo XXI]. Barcelona: Ars Medica, 2002, p. 26-32.
95. Girón M, Manjón-Arce P, Puerto-Barber J, Sánchez-García E, Gómez-Beneyto M. Clinical interview skills and identification of emotional disorders in primary care. Am J Psychiatry. 1998; 155(4): 530-5.
96. Cox JL. Empathy, identity and engagement in person-centered medicine: the sociocultural context. J Eval Clin Pract. 2011; 17(2):350-3.
97. van Dulmen S. The value of tailored communication for personcentred outcomes. J Eval Clin Pract. 2011; 17(2):381-3
98. Elbogen EB, Swartz MS, Van Dorn R, Swanson JW, Kim M, Scheyett A. Clinical decision making and views about psychiatric advance directives. Psychiatr Serv. 2006; 57: 350-355.
99. Wilder CM, Elbogen EB, Moser LL, Swanson JG, Swartz MS. Medication Preferences and Adherence Among Individuals With Severe Mental Illness and Psychiatric Advance Directives. Psychiatr Serv. 2010; 61: 380-385.
100. Campbell LA, Kisely S. Prescribing preferred medications improves adherence in people with severe mental illness. Evid Based Ment Health. 2010; 13: 108
101. Aitken PV. Incorporating advance care planning into family practice. Am Fam Physician 1999; 59: 605-620.
102. O'Connell MJ, Stein CH. Psychiatric advance directives: perspective of community stakeholders. Adm Policy Ment Health. 2005; 32: 241-265.
103. Atkinson JM, Garner HC, Gilmour WH. Models of advance directives in mental health care: stakeholder views. Soc Psychiatry Psychiatr Epidemiol. 2004; 39: 673-680.
104. Ho BC, Andreasen NC, Ziebell S, Pierson R, Magnotta V. Longterm antipsychotic treatment and brain volumes: a longitudinal study of first-episode schizophrenia. Arch Gen Psychiatry. 2011; 68(2):128-37.
105. Ayuso-Mateos JL. Conventional antiepileptic drugs are not associated with an increased risk of suicidal behaviour or selfharm. Evid Based Ment Health. 2011; 14(1): 2.
106. Salvador-Carulla L, Rodríguez-Blázquez C. Psychosocial modifiers of drug prescription: the hidden face of pharmacology? Pharmacoepidemiol Drug Saf. 1998; 7(1): 23-9.
107. Appelbaum PS, Gold A. Psychiatrists' relationships with industry: the principal-agent problem. Harv Rev Psychiatry. 2010; 18(5): 255-65.
108. Moncrieff J, Hopker S, Thomas P. Psychiatry and the pharmaceutical industry: who pays the piper? A perspective from the Critical Psychiatry Network. Psychiatric Bull. 2005; 29: 84-85.
109. Smith R. Medical Journals are an extension of the marketing arm of pharmaceutical companies. PLoS Med. 2005; 2: e138.
110. Eisenberg L. [Psychiatry and human rights: putting the good of the patient first]. Actas Esp Psiquiatr. 2009; 37(1): 1-8.
111. Mezzich JE, Salloum IS, Cloninger R, Salvador-Carulla L, Kirmayer LJ, Banzato CEM, Wallcraft J, Botbol M. Person-centred Integrative Diagnosis: Conceptual Bases and Structural Model. Can J Psychiatry. 2010; 55: 701-8.